Flomics is developing a new diagnostic test for the early-detection of cancer and other complex diseases. Its technology combines cell-free RNA sequencing with automated analysis by machine learning. From a simple blood sample it aims to detect molecular warning signs of the disease, even before the first symptoms appear. Flomics was one of the ten European projects chosen to to participate in the 2nd edition of CRAASH Barcelona, the acceleration program Biocat organized in collaboration with CIMIT (Boston) which is part of the bootcamp programs run by EIT Health (Biocat has just opened this month the call for the 3rd edition of CRAASH Barcelona. You can read here Flomics's experience in CRAASH Barcelona). João Curado is the founder of Flomics.
I believe I'm a scientist by training and an entrepreneur by passion. I like to learn, to explore and, very importantly, to manage the risk. It was a natural decision. During my entire career I explored opportunities to design and launch new projects and it's what I believe I'm good at.
To get proper help in the tasks and skills that we are not good at.
There's no magic formula that always works. We can talk with different experts that give different opinions and they may be all right. In the end of the day, the founders are the ones that need to make decisions.
We are starting the validation phase of our first diagnosis model, in colon cancer. We hope it will open some doors in the diagnosis market. In parallel, we are starting new collaborations with hospitals and research institutions in order to replicate the success of the first project but in different diseases, where an early diagnosis is key to optimize the treatment and to save lives